bluuebunny/crossref_metadata_2025_split huggingface dataset:
1327. Correlates of Need for Ancillary Service Referrals Among Persons Receiving HIV Care in New York City: Findings From the Medical Monitoring Project
Authors: Navejas Michael , Raj Singh Shavvy , Huang Jamie , Udeagu Chi-Chi N 
Published: October 2019

Abstract

Background
Retention of people with HIV (PWH) in HIV care is essential for optimal health outcomes. Unmet needs for ancillary services, such as housing, food, transportation, or mental health services may pose barriers to sustained retention in HIV care.

Methods
A representative sample of people with HIV (PWH) aged ≥18 years and receiving HIV care in NYC between 2015 and 2016 was interviewed for the Medical Monitoring Project (MMP). Questions attempted to identify needs for ancillary services among participants. We explored correlates of expressed needs for ancillary services in the 12 months prior to the interview date.

Results
Of 654 PWH interviewed, 650 (99%) were current with HIV care. Of these, 323 (50%) expressed a need for ancillary services. Among the 323 PWH expressing needs, 209 (65%) were males, 163 (50%) were non-Hispanic blacks, 118 (37%) were Hispanic, and 111 (35%) were individuals identifying as gay (26%) or lesbian (9%).The median age was 50 [interquartile range (IQR) 40–58 years]. In the multivariate model, non-Hispanic blacks (OR: 2.5; 95% CI: 1.4, 4.6) and Hispanics (OR: 2.5; 95% CI: 1.4, 4.7) had higher odds than whites of expressing current needs for ancillary services. A higher need for ancillary services was expressed by PWH that were virally suppressed vs. not suppressed (OR: 1.7; 95% CI: 1.0, 3.0) and those with a history of injection drug use vs. those without (OR 2.2; 95% CI: 1.3, 3.7).

Conclusion
Half of the PWH in our sample expressed a current need for ancillary services despite being actively engaged in HIV. Providers should routinely screen their patients, especially non-Hispanic black and Hispanic patients and persons with substance use history, for unmet needs and proactively link them to social service providers in order to promote overall well-being and retention in HIV care.

Disclosures
All authors: No reported disclosures.
1350. Clofazimine as an Oral Companion Drug for Treatment of Mycobacterium abscessus complex Infections
Authors: Yong Joy , Lip Chew Ka , Tambyah Paul 
Published: October 2019

Abstract

Background
Infections caused by the multi-drug-resistant Mycobacterium abscessus complex (MabsC) are challenging to treat and often require multiple antimicrobials for a prolonged treatment course and still have poor outcomes. Clofazimine, an oral anti-leprosy drug, has demonstrated good in vitro susceptibility and is being increasingly employed in treatment regimens for MabsC infections. We performed a drug-use-evaluation of clofazimine in the treatment of MabsC infections.

Methods
A retrospective review was performed for all patients with MabsC infections treated with clofazimine-containing regimens from January 2014 to June 2017.

Results
Twenty-nine patients were included. Twelve patients had pulmonary MabsC infections and seventeen had extrapulmonary infections. All isolates had clofazimine minimum-inhibitory-concentration of ≤0.5 mg/L as tested by broth microdilution. Clofazimine was prescribed at initiation of therapy in 31.0% (9/29), as a companion drug during maintenance therapy after initial intravenous therapy in 44.8% (13/29) and as part of salvage therapy due to disease progression or drug intolerance in 24.1% (7/29) of patients. Dosing of clofazimine for the pediatric patients was prescribed at 1–2 mg/kg/day while the adult patients received a range of 50–200 mg/day. Clofazimine was given for a median duration of 148.5 days (range: 14–1212) and most commonly in combination with clarithromycin (82.8%), amikacin (58.6%), and cefoxitin (24.1%). Twelve patients had documented adverse reactions attributable to clofazimine: skin hyperpigmentation (66.7%), abnormal liver function tests (16.7%), and gastrointestinal disturbance (16.7%). Table 1 describes the patients who had clofazimine ceased due to an adverse effect. Nine patients with pulmonary MabsC infections and 16 with extrapulmonary MabsC infections had documented improvement in symptoms.

Conclusion
Clofazimine as a companion drug in the treatment of MabsC infections was reasonably tolerated over a prolonged period of time. Its availability as an oral active agent makes it an attractive alternative to IV companion drugs and potentially improves compliance to the protracted treatment courses for patients with MabsC infections.

Disclosures
All authors: No reported disclosures.
1390. A Novel Application of the Interferon-Gamma Release Assay (IGRA) Among End-Stage Heart Failure Patients Awaiting Heart Transplantation
Authors: Tsai Ming-Jui , Cheng Aristine , Sun Hsin-Yun , Chen Yih-Sharng , Chou Nai-Kuan , Wang Sheoi-Shen , Chen Yee-Chun , Chang Shan-Chwen 
Published: October 2019

Abstract

Background
The optimal approach to assay the immune status in heart failure is challenging because of the inherent complexity of chronic inflammation. Interferon-gamma release assays (IGRAs) measure an aspect of cell-mediated immunity encompassing both the innate and adaptive immunity. In this study, we evaluated the utility of a commercial IGRA for predicting mortality and infectious complications among heart transplant candidates.

Methods
This prospective cohort study was conducted between August 1, 2014 and January 31, 2019 at a medical center in Taiwan. All heart transplant candidates received an IGRA (QuantiFERON®-TB Gold In-Tube, QFT-GIT) at baseline as part of the initiative to screen for latent tuberculosis. Impaired cell-mediated immunity was defined as the release of <1 IU/mL of interferon-γ (IFN-γ) in response to the common mitogen in the positive control tube.The patients were then followed until death or January 31, 2019.

Results
A total of 102 patients were enrolled; of whom, 23 (22.5%) had impaired cell-mediated immunity at baseline. During the study period with a median follow-up of 1.90 years (IQR 1.17–3.56), 23 (22.5%) patients died and 45 (44.1%) patients developed an infectious complication. Overall mortality was significantly greater among those with impaired cell-mediated immunity [39.1% (9/23) vs. 17.7% (14/79), P = 0.031]. A trend toward higher rates of infection was observed among impaired cell-mediated immunity group [60.9% (14/23) vs. 39.2% (31/79), P = 0.066]. The most common cause of death was infection (56.5%). No patient developed active tuberculosis during the study and the most common infection was bacteremia (35.6%). In the age-adjusted multivariate analysis, impaired cell-mediated immunity was an independent predictor of mortality (HR 2.87, CI 1.23–6.68, P = 0.014) and subsequent infectious event (HR 3.00, CI 1.56–5.76, P = 0.001).

Conclusion
An interferon-γ release assay utilizing the positive control tube of the QuantiFERON®-TB Gold In-Tube kit was predictive of overall mortality and infections among patients with advanced heart failure awaiting heart transplantation.

Disclosures
All authors: No reported disclosures.
1404. The FilmArray Meningitis/Encephalitis (FA ME) May Be of Higher Yield in the Immunocompromised Patient Population
Authors: Mehta Nirja , Jacob Jesse T , Dean Christina , Wiley Zanthia , Burd Eileen , Kraft Colleen 
Published: October 2019

Abstract

Background
The FilmArray® Meningitis/Encephalitis (FA ME) panel is a PCR-based assay that rapidly detects 14 pathogens directly from CSF specimens. After the introduction of this assay at our institution, there was a steady increase in requests for use; however, the positivity rate remained stable. We sought to understand the characteristics of the patients most likely to have a positive FA ME panel, with particular interest in the immune status of each patient.

Methods
A retrospective chart review was conducted on 124 patients with suspected infectious meningitis/encephalitis at a large academic tertiary referral center who received FA ME testing between October 2016 and November 2018. Patients were considered immunocompromised if they had received chemotherapy, were solid-organ transplant recipients, or were diagnosed with HIV, autoimmune diseases on immunosuppressants, uncontrolled diabetes, cirrhosis, or hematologic malignancy. Clinical CNS infection was determined using chart review based on culture, serologic, or molecular data.

Results
60 (48%) patients were immunocompromised and 64 (52%) patients were immunocompetent. Clinical CNS infection occurred in ~25% of immunocompetent (17, 26%) and immunocompromised (17, 28%) patients. However, only 6 immunocompetent patients were found to have a positive FA ME; this accounts for only 35% of the total number of positive FA ME assays during this study period (P = 0.08). Notably, 4 out of 6 patients with cryptococcal meningitis had false-negative results on the FA ME.

Conclusion
In spite of the relatively small sample size, there was a trend toward significance in the accurate yield of the FA ME panel in the immunocompromised population compared with the immunocompetent. Our immunocompromised patients appear to be more likely to have an infection which is tested for on the panel. The rates of confirmed CNS infections in both populations were very similar, indicating that immunocompromised patients may benefit more from use of this assay. In our study, immunocompetent patients were more likely to have West Nile infection, for example, which is not on the panel. Additionally, had cryptococcal meningitis been accurately diagnosed by the FA ME, an even greater number of immunocompromised patients would have had a positive FA ME.

Disclosures
All authors: No reported disclosures.
1411. Differentiation of Fungal Abscess of Brain From Brain Glioblastoma by MRI Scan ADC Value
Authors: Aziz Kashif , Nawaz Atif 
Published: October 2019

Abstract

Background
Differentiation of Brain fungal abscess from brain glioblastoma is very important. Treatment strategies are different in both cases. Glioblastoma needs different surgical planning as compared with abscess. We hypothesized that preoperative MRI brain will help in differentiation.

Methods
A retrospective study was carried out at Aga Khan University Hospital Karachi. Data from 2007 to 2017 was retrieved from Medical records using ICD-9 coding. 90 patients (47 males and 43 females; age range 10–70 years) with aggressive grade IV brain lesion and fungal abscess was selected and their preoperative MRI data were retrieved. The apparent diffusion coefficient (ADC) maps were reconstructed from diffusion-weighted imaging DWI data. The mean ADC value and standard deviation of glioblastoma and fungal abscesses were calculated. Postoperative biopsy results were used as gold standard.The analysis of data was done to test statistically significant differences between glioblastoma and fungal brain abscess. Receiver operating characteristic (ROC) curve was used to determine the cut-off point with highest accuracy that was used to differentiate malignancy from infection. The statistical analysis of data was done using SPSS® v. 19.

Results
The mean (±standard deviation) ADC value of fungal brain abscess (826.040 ± 94.97 × 0.001 mm2/sec) was significantly lower than that of glioblastoma (1,462.800 ± 163.66 × 0.001 mm2/sec). When an ADC value of 1,200 × 0.001 mm2/s used as a cutoff value for differentiating fungal abscess from glioblastoma the best result was obtained with an accuracy of 85%, sensitivity of 81%, specificity of 88%, negative predictive value of 80%, and positive predictive value of 90%.

Conclusion
ADC value is a noninvasive promising imaging parameter that can be used for differentiation of fungal brain abscess and glioblastoma on preoperative scan. The cut-off value with best accuracy in our study was 1,200 × 0.001 mm2/s.

Disclosures
All authors: No reported disclosures.
1414. Time-to-Completed-Imaging, Survival, and Function in Patients with Spinal Epidural Abscess: Description of a Series of 34 Patients, 2015–2018
Authors: King Caroline , Fisher Cameron , Brown Patrick , Priest Kelsey , Tanski Mary , Sullivan Peter 
Published: October 2019

Abstract

Background
Spinal epidural abscess (SEA) is a rare and life-threatening infection with increased incidence over the past two decades. Delays in diagnosis cause significant morbidity and mortality among patients. The objective of this study was to describe average time-to-imaging and frequencies of intervention, risk factors, and outcomes among patients with SEA presenting to an emergency department at a single academic health center in Portland, Oregon.

Methods
This retrospective cohort study reviewed data from patients with no prior history of SEAs at a single hospital from October 1, 2015 to April 1, 2018. We report measures of central tendency and frequencies of collected information.

Results
Of the 34 patients included, seven (20%) died or were discharged with plegia during the study period. Four others (11.8%) had motor weakness, and four (11.8%) patients had new bowel or bladder dysfunction at discharge. Those who died or were discharged with plegia (n = 7) had shorter mean time-to-imaging order (20.8 hours vs. 29.2 hours). Patients with a history of intravenous drug use had a longer mean time-to-imaging order (30.2 hours vs. 23.7 hours) vs. those without a history of intravenous drug use. Furthermore, only three (42.9%) of the seven patients who died or acquired plegia presented with the three symptom classic triad of SEA: (1) fever; (2) abnormal neurologic examination or symptoms; and (3) neck or back pain.

Conclusion
SEA is a potentially deadly infection requiring prompt identification and treatment. This research provides baseline data for potential quality improvement work at the study site. Future research should evaluate multi-center approaches for identifying and intervening to treat SEA, particularly among patients with a history of intravenous drug use.

Disclosures
All authors: No reported disclosures.
1418. Clinical Characteristics of Vertebral Osteomyelitis in Cancer Patients
Authors: Fukushima Kazuaki , Horiuchi Masao , Sekiya Noritaka 
Published: October 2019

Abstract

Background
Vertebral osteomyelitis (VOM) is an infection of vertebrae or intervertebral disc and associated with high mortality, decreased functional status, prolonged antibiotic use and recurrent infection. Although most of the patients with VOM often embody immunodeficiency or other comorbidities, characteristics of VOM in cancer patients remain to be fully elucidated. The aim of this study was to describe clinical profile, underlying disease, lesion site, pathogen, comorbidities, treatment, and outcome in patients with cancer.

Methods
This study was a retrospective observational study in a tertiary care cancer hospital with 801 beds. All patients with VOM were diagnosed by computed tomography or magnetic resonance imaging from July 2004 to March 2019. Culture-confirmed VOM was defined when causative pathogens were identified from the lesion site including vertebra, intervertebral disc, paravertebral or epidural abscess or when the result of blood culture was positive with compatible clinical symptoms. Data including patient characteristics, underlying diseases, lesion sites, type of infection, entry site of infection, results of bacterial culture, treatment, and outcome were collected by electronic medical records. We analyzed data of patients with culture-confirmed VOM between patients with cancer (C-VOM) and patients without cancer (NC-VOM). Death or re-treatment was the primary outcome. Statistical analysis was performed by STATA Version 15.

Results
Total number of patients diagnosed with VOM was 101, of which culture-confirmed VOM was 61 (C-VOM: 30 and NC-VOM: 31). Age, lesion sites, pathogen, or comorbidities were not significantly different between two groups (table). On the other hand, the rate of contiguous infection in C-VOM was significantly higher than NC-VOM (20.0 % vs. 0.0 %; P = 0.01). Univariate cox proportional hazard model revealed that cancer was risk of death or re-treatment (HR:3.14, 95% CI:1.07–9.24).

Conclusion
Poor prognosis and contiguous infection from adjacent infection sites should be concerned cancer patients with culture-confirmed VOM.

Disclosures
All authors: No reported disclosures.
1419. A Rare Case of Clostridium beijerinckii Traumatic Osteomyelitis
Authors: Doktor Katherine L , Heffernan Kelsey , Drames Danielle , Byrne Dana D 
Published: October 2019

Abstract

Background
We present a case of Clostridium beijerinckii osteomyelitis in the presence of retained foreign bodies not seen on MRI.

Methods
A 45-year-old female with type 2 diabetes sustained multiple open right leg injuries, grossly contaminated with gravel, after a motor vehicle collision. She underwent external fixation (ex-fix) and 5 irrigations and debridements (I&D) initially. Polymicrobial intraoperative cultures (Cx) were treated with vancomycin and ertapenem for 6 weeks. One month post-antibiotic completion, pain, and swelling developed in ankle; contrast MRI revealed avascular necrosis and osteomyelitis (OM) of talus. Cx from repeat I&D grew same organisms; meropenem was recommended for 6 weeks. During meropenem week 6, pain was minimal and wound was closed. During attempt to implant hardware, pus was seen around peroneal tendon. Cx grew Clostridium species and Bacteroides from tibia, calcaneus, talus, and peroneal tendon sheath; meropenem was continued. Pain worsened 3 weeks later; I&D revealed pus in lateral ankle. To better access the medial ankle, a longitudinal incision was made along posterior tibial tendon, perpendicular to prior surgical incision. Immediate purulence, grass blades, and rocks were seen. Brucella agar had a rare gray colony at 48 hours and was subbed to blood and Brucella agar; it grew on Brucella agar with aero tolerance test. Gram stain showed Gram-positive rods with subterminal spores. Rapid ANA panel identified isolate as Clostridium beijerinckii (Cb) with > 99.9% probability and bioscore 1/24.

Results
Cb is a strict anaerobic gram-positive rod with oval subterminal spores. Found in soil and water, its main use is industrial solvent production. Infection by Cb is rare; only 2 cases of OM, 1 traumatic endophthalmitis, and 1 mitral valve endocarditis have been reported. While uncommon, Clostridial osteomyelitis is associated with contaminated open traumatic injuries. It can be difficult to eradicate, despite aggressive surgical intervention and appropriate antibiotics.

Conclusion
This is the third case of Cb OM described. Anaerobic cultures should be collected during I&D of open traumatic wounds. If infection persists, careful intraoperative evaluation of wound for residual foreign bodies, even if not seen radiologically, should be performed.

Disclosures
All authors: No reported disclosures.
1475. Understanding Prescribing Practices for Uncomplicated Urinary Tract Infections (UTIs) in the Primary Care Setting: A Pilot Study
Authors: Pinkerton Mark , Bongu Jahnavi , James Aimee , Durkin Michael 
Published: October 2019

Abstract

Background
Uncomplicated urinary tract infections (UTIs) should be treated empirically with a short course of narrow-spectrum antibiotics. However, many clinicians order unnecessary tests and treat with long courses of antibiotics. The objective of this study was to understand how internists clinically approach UTIs.

Methods
We conducted semi-structured qualitative interviews of community primary care providers (n = 15) and internal medicine residents (n = 15) in St. Louis, Missouri from 2018 to 2019 to explore why clinical practices deviate from evidence-based guidelines. Interviews were transcribed, de-identified, and coded by two independent researchers using NVivo qualitative software. A Likert scale was used to evaluate preferences for possible interventions.

Results
Several common themes emerged. Both providers and residents ordered urine tests to “confirm” presence of urinary tract infections. Antibiotic prescriptions were often based on historical practice and anecdotal experience. Providers were more comfortable treating over the phone than residents and tended to prescribe longer courses of antibiotics. Both providers and residents voiced frustrations with guidelines being difficult to easily incorporate due to length and extraneous information. Preferences for receiving and incorporating guidelines into practice varied. Both groups felt benchmarking would improve prescribing practices, but had reservations about implementation. Pragmatic clinical decision support tools were favored by providers, with residents preferring order sets and attendings preferring nurse triage algorithms.

Conclusion
Misconceptions regarding urinary tract infection management were common among residents and community primary care providers. Multifaceted interventions that include provider education, synthesis of guidelines, and pragmatic clinical decision support tools are needed to improve antibiotic prescribing and diagnostic testing; optimal interventions to improve UTI management may vary based on provider training level.

Disclosures
All authors: No reported disclosures.
1483. Comparison of Outcomes in Urinary Tract Infections Caused by SPICE Organisms Treated with Non-Carbapenem-β-lactams vs. Non-β-lactams Agents
Authors: Sapozhnikov Julia , Huang Angela , Powell Kelsey , Gibble Allison 
Published: October 2019

Abstract

Background
The “SPICE organisms” intrinsically produce low levels of a chromosomally encoded β-lactamase enzyme, AmpC. When SPICE organisms are exposed to certain antimicrobial agents, they can select for de-repressed mutants and induce the AmpC gene. No study to date has determined the optimal treatment of lower inoculum infections such as urinary tract infections (UTIs) caused by SPICE organisms.

Methods
This study is a single-center, retrospective observational review of adult hospitalized patients with a UTI caused by a SPICE organism from November 2012 to November 2015. The objective of this study was to compare outcomes amongst patients with UTIs caused by select SPICE organisms treated with drugs susceptible to AmpC hydrolysis (penicillins, cephalosporins except cefepime, and monobactams) vs. drugs stable against AmpC (carbapenems, cefepime, and non-β-lactam agents). The primary outcome was clinical response, defined as resolution of signs and symptoms of UTI without requiring escalation of antimicrobial therapy after 48 hours of therapy initiation. Secondary outcomes include 30-day infection-related readmission, 30-day infection recurrence rate, 30-day all-cause mortality, and length of hospital stay. Patients with resistance to ceftriaxone were reviewed for β-lactam exposure (≥7 days) within the last month.

Results
One-hundred 56 patients were identified. Clinical response, 30-day infection-related readmission, 30-day infection recurrence, 30-day mortality rates, and median length of hospital stay were similar between the AmpC stable and AmpC susceptible groups (Table 1). Notably, 39.1% of patients with ceftriaxone resistance reported had recent β-lactam exposure vs. only 11.6% of patients without ceftriaxone resistance (P = 0.0028).

Conclusion
Based our data, there does not appear to be a difference in clinical response, 30-day-related readmission, 30-day infection recurrence, 30-day all-cause mortality rates, or length of stay in patients with UTIs treated with AmpC stable and AmpC susceptible agents. AmpC induction can be seen with at least 7 days of β-lactam use in the past 30 days as demonstrated by more frequent use of recent β-lactam agents in those with ceftriaxone resistance detected.

Disclosures
All authors: No reported disclosures.